pyrazines has been researched along with Adenohypophyseal Hyposecretion in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hjelholt, AJ; Jessen, N; Jørgensen, JOL; Møller, N; Pedersen, SB; Søndergaard, E | 1 |
| Cichosz, SL; Fleischer, J; Jørgensen, JOL; Møller, N; Vestergaard, ET | 1 |
| Gribble, FM; Hjelholt, AJ; Holst, JJ; Jessen, N; Jørgensen, JOL; Kuhre, RE; Larraufie, P; Møller, N; Reimann, F; Vestergaard, ET | 1 |
| Cattaneo, A; Cavagnini, F; Fatti, LM; Filippini, B; Grasso, A; Moro, M; Orsini, F; Pecori Giraldi, F; Scacchi, M | 1 |
| Alvarez-Castro, P; Casanueva, FF; Cordido, F; Dieguez, C; Isidro, ML | 1 |
| Casanueva, FF; Cordido, F; Dieguez, C; Fernandez, T; Martinez, T; Peinó, R; Peñalva, A | 1 |
4 trial(s) available for pyrazines and Adenohypophyseal Hyposecretion
| Article | Year |
|---|---|
Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cross-Over Studies; Denmark; Double-Blind Method; Fatty Acids, Nonesterified; Heart; Heart Rate; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Lipolysis; Male; Parasympathetic Nervous System; Pyrazines; Time Factors; Treatment Outcome | 2017 |
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Topics: Adult; Animals; Blood Glucose; Cells, Cultured; Cross-Over Studies; Enteroendocrine Cells; Fatty Acids, Nonesterified; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin Resistance; Intestinal Mucosa; Lipolysis; Male; Middle Aged; Overweight; Pilot Projects; Primary Cell Culture; Pyrazines; Rats | 2019 |
Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Topics: Adult; Body Mass Index; Evaluation Studies as Topic; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Male; Middle Aged; Obesity; Oligopeptides; Pyrazines | 2003 |
Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Topics: Adult; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Male; Middle Aged; Obesity; Pyrazines | 1998 |
2 other study(ies) available for pyrazines and Adenohypophyseal Hyposecretion
| Article | Year |
|---|---|
Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.
Topics: Adipose Tissue; Adult; Aged; Angiopoietin-Like Protein 4; Cross-Over Studies; Fatty Acids; Fatty Acids, Nonesterified; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Lipoprotein Lipase; Male; Middle Aged; Obesity; Pyrazines; RNA, Messenger; Single-Blind Method; Up-Regulation; Young Adult | 2020 |
The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Topics: Adult; Aged; Arginine; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Insulin-Like Growth Factor I; Linear Models; Lipolysis; Male; Middle Aged; Obesity; Pyrazines | 2010 |